Werewolf Therapeutics, Inc. ( (HOWL) ) has released its Q3 earnings. Here is a breakdown of the information Werewolf Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics to stimulate the immune system for cancer treatment, operating primarily in the biotechnology sector.
In its latest earnings report for the quarter ended September 30, 2025, Werewolf Therapeutics highlighted a continued focus on research and development, despite facing financial challenges typical of early-stage biotech firms. The company reported a net loss, reflecting ongoing investments in its product pipeline.
Key financial metrics revealed a net loss of $16.4 million for the quarter, with total operating expenses amounting to $15.7 million. The company ended the quarter with $65.7 million in cash and cash equivalents, a decrease from the previous year, indicating significant cash burn due to its development activities. Werewolf also raised $3.6 million through an at-the-market offering of common stock during the period.
Looking ahead, Werewolf Therapeutics remains focused on advancing its INDUKINE and INDUCER molecules, although it acknowledges the need for additional funding to sustain operations and complete product development. The company is exploring various financing strategies to address its capital requirements and continue its innovative work in cancer therapeutics.